Search This Blog

Friday, June 20, 2025

Sana Bio to Present Novel Immunosuppression-Free Diabetes Cell Therapy Data at ADA

Sana Biotechnology (NASDAQ: SANA) will present updated six-month clinical results for UP421, their hypoimmune-modified primary islet cell therapy for type 1 diabetes, at the 85th Annual American Diabetes Association Scientific Sessions. The presentation, scheduled for June 23, 2025, in Chicago, will highlight data from a first-in-human study where UP421, an allogeneic primary islet cell therapy using Sana's hypoimmune (HIP) technology, was transplanted into a patient without requiring immunosuppression. The presentation will be part of a joint symposium between the American Diabetes Association (ADA) and International Pancreas & Islet Transplant Association (IPITA) focused on immune protection for cell replacement therapy.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.